GlassScriptPhysician profile
Khiem Tuong Vu
NPI 1164926077
$5,662.27
in general payments reported to CMS, 2019-2025
28 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2022: $257 · 2023: $1,273 · 2024: $2,513 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,123 · Education: $23.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,123.31 |
| Education | $23.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $964.91 | 2023-2025 | Evenity, Prolia, Tavneos |
| Abbvie INC. | $884.01 | 2022-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $716.09 | 2023-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $489.09 | 2022-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $379.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $340.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $326.56 | 2023-2025 | Benlysta |
| Genzyme Corporation | $259.78 | 2023-2024 | |
| Biotronik Nro, INC. | $257.90 | 2024 | Prospera |
| E.R. Squibb & Sons, L.L.C. | $165.39 | 2023-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.24 | 2023-2024 | Cyltezo |
| Johnson & Johnson Health Care Systems INC. | $150.00 | 2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Fresenius Kabi USA, LLC | $95.18 | 2023-2025 | Idacio, Tyenne |
| Lilly USA, LLC | $64.28 | 2022-2024 | Taltz, Zepbound |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $40.39 | 2023-2024 | Purified Cortrophin Gel |
| Tonix Medicines, INC. | $34.14 | 2025 | Tonmya |
| Radius Health, INC. | $27.61 | 2023 | Tymlos |
| Bioventus LLC | $27.41 | 2023 | Supartz Fx Sodium Hyaluronate |
| Alexion Pharmaceuticals, INC. | $24.85 | 2024 | Strensiq |
| Celltrion USA INC. | $23.57 | 2023 | Yuflyma |
| Fidia Pharma USA INC. | $18.94 | 2025 | Hymovis, Triluron |
| Aurinia Pharma U.S., INC. | $17.23 | 2023 | Lupkynis |
| Genentech USA, INC. | $15.97 | 2024 | Actemra |
| Zimmer Biomet Holdings, INC. | $14.85 | 2024 | Gps III Platelet Concentration System |
| Medtronic, INC. | $14.28 | 2024 | Intellis Adaptivestim |
| Tersera Therapeutics LLC | $14.12 | 2025 | Quzyttir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khiem Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.